| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.851 | 0.004 | 0.851 | Anticonvulsant | 0.748 0.005 DBMET00285 | ||
| 0.747 | 0.003 | 0.747 | Anesthetic general | 0.686 0.004 DBMET00285 | ||
| 0.744 | 0.004 | 0.744 | Psychostimulant | 0.548 0.008 DBMET00285 | ||
| 0.669 | 0.008 | 0.669 | Spasmolytic | 0.523 0.02 DBMET00285 | ||
| 0.542 | 0.003 | 0.563 | Lipocortins synthesis antagonist | 0.563 0.003 DBMET00285 | DBMET00285 | |
| 0.485 | 0.004 | 0.579 | Nav1.1 sodium channel blocker | 0.579 0.003 DBMET00285 | DBMET00285 | |
| 0.47 | 0.037 | 0.614 | Aldehyde oxidase inhibitor | 0.614 0.017 DBMET00285 | DBMET00285 | |
| 0.395 | 0.005 | 0.395 | 5 Hydroxytryptamine 7 antagonist | 0.22 0.01 DBMET00285 | ||
| 0.382 | 0.008 | 0.401 | Nav1.2 sodium channel blocker | 0.401 0.007 DBMET00285 | DBMET00285 | |
| 0.407 | 0.058 | 0.452 | GABA C receptor rho-3 antagonist | 0.452 0.041 DBMET00285 | DBMET00285 | |
| 0.36 | 0.023 | 0.36 | Cyclic AMP phosphodiesterase inhibitor | 0.316 0.036 DBMET00285 | ||
| 0.341 | 0.042 | 0.341 | Cardiotonic | 0.313 0.051 DBMET00285 | ||
| 0.359 | 0.07 | 0.359 | Vasodilator, peripheral | 0.306 0.094 DBMET00285 | ||
| 0.31 | 0.03 | 0.348 | RNA-directed DNA polymerase inhibitor | 0.348 0.024 DBMET00285 | DBMET00285 | |
| 0.282 | 0.004 | 0.282 | Phosphodiesterase 4C inhibitor | 0.148 0.008 DBMET00285 | ||
| 0.262 | 0.013 | 0.31 | Nav1.3 sodium channel blocker | 0.31 0.008 DBMET00285 | DBMET00285 | |
| 0.337 | 0.094 | 0.353 | Immunosuppressant | 0.353 0.085 DBMET00285 | DBMET00285 | |
| 0.251 | 0.009 | 0.329 | Nav1.6 sodium channel blocker | 0.329 0.005 DBMET00285 | DBMET00285 | |
| 0.237 | 0.008 | 0.237 | Phosphodiesterase 4D inhibitor | 0.157 0.018 DBMET00285 | ||
| 0.283 | 0.06 | 0.283 | Tumour necrosis factor alpha release inhibitor | 0.261 0.07 DBMET00285 | ||
| 0.359 | 0.141 | 0.456 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.456 0.058 DBMET00285 | DBMET00285 | |
| 0.29 | 0.082 | 0.328 | Immunostimulant | 0.328 0.071 DBMET00285 | DBMET00285 | |
| 0.238 | 0.034 | 0.263 | Tumour necrosis factor antagonist | 0.263 0.027 DBMET00285 | DBMET00285 | |
| 0.311 | 0.118 | 0.311 | Histamine release inhibitor | 0.273 0.14 DBMET00285 | ||
| 0.197 | 0.014 | 0.214 | Antineoplastic alkaloid | 0.214 0.01 DBMET00285 | DBMET00285 | |
| 0.253 | 0.072 | 0.253 | 5 Hydroxytryptamine 1E antagonist | 0.221 0.108 DBMET00285 | ||
| 0.202 | 0.022 | 0.263 | Ferrochelatase inhibitor | 0.263 0.012 DBMET00285 | DBMET00285 | |
| 0.196 | 0.019 | 0.196 | Bronchodilator | 0.146 0.033 DBMET00285 | ||
| 0.243 | 0.071 | 0.303 | DNA synthesis inhibitor | 0.303 0.042 DBMET00285 | DBMET00285 | |
| 0.25 | 0.081 | 0.27 | 5 Hydroxytryptamine uptake stimulant | 0.27 0.063 DBMET00285 | DBMET00285 | |
| 0.188 | 0.036 | 0.227 | GABA C receptor rho-2 antagonist | 0.227 0.017 DBMET00285 | DBMET00285 | |
| 0.264 | 0.115 | 0.264 | Cholesterol antagonist | 0.264 0.115 DBMET00285 | ||
| 0.173 | 0.026 | 0.173 | GABA receptor agonist | 0.173 0.026 DBMET00285 | ||
| 0.261 | 0.123 | 0.276 | Vasodilator, coronary | 0.276 0.108 DBMET00285 | DBMET00285 | |
| 0.229 | 0.092 | 0.26 | Tyrosine 3 hydroxylase inhibitor | 0.26 0.059 DBMET00285 | DBMET00285 | |
| 0.225 | 0.093 | 0.289 | Superoxide dismutase inhibitor | 0.289 0.054 DBMET00285 | DBMET00285 | |
| 0.246 | 0.126 | 0.276 | Thyroid hormone antagonist | 0.276 0.107 DBMET00285 | DBMET00285 | |
| 0.142 | 0.023 | 0.149 | Electrolyte absorption antagonist | 0.149 0.02 DBMET00285 | DBMET00285 | |
| 0.121 | 0.007 | 0.121 | Phosphodiesterase 1A inhibitor | 0.103 0.009 DBMET00285 | ||
| 0.168 | 0.062 | 0.19 | Diuretic | 0.19 0.048 DBMET00285 | DBMET00285 | |
| 0.214 | 0.11 | 0.272 | 5 Hydroxytryptamine release stimulant | 0.272 0.079 DBMET00285 | DBMET00285 | |
| 0.124 | 0.021 | 0.124 | Phosphodiesterase 6D inhibitor | 0.099 0.054 DBMET00285 | ||
| 0.126 | 0.024 | 0.126 | Phosphodiesterase I inhibitor | 0.119 0.027 DBMET00285 | ||
| 0.131 | 0.031 | 0.144 | DNA directed RNA polymerase inhibitor | 0.144 0.026 DBMET00285 | DBMET00285 | |
| 0.296 | 0.198 | 0.355 | Caspase 9 stimulant | 0.355 0.141 DBMET00285 | DBMET00285 | |
| 0.163 | 0.066 | 0.177 | Cytidine deaminase inhibitor | 0.177 0.058 DBMET00285 | DBMET00285 | |
| 0.11 | 0.014 | 0.11 | Phosphodiesterase 4A inhibitor | 0.043 0.04 DBMET00285 | ||
| 0.143 | 0.048 | 0.143 | Acetylcholine muscarinic antagonist | 0.111 0.077 DBMET00285 | ||
| 0.114 | 0.024 | 0.118 | HIV-1 reverse transcriptase inhibitor | 0.118 0.023 DBMET00285 | DBMET00285 | |
| 0.145 | 0.058 | 0.145 | Heat shock protein 70 antagonist | |||
| 0.192 | 0.111 | 0.284 | Vasodilator | 0.284 0.054 DBMET00285 | DBMET00285 | |
| 0.123 | 0.043 | 0.128 | Acetylcholine release stimulant | 0.128 0.037 DBMET00285 | DBMET00285 | |
| 0.207 | 0.138 | 0.232 | Gastrin inhibitor | 0.232 0.102 DBMET00285 | DBMET00285 | |
| 0.105 | 0.036 | 0.105 | Acetylcholine nicotinic antagonist | 0.079 0.056 DBMET00285 | ||
| 0.187 | 0.118 | 0.254 | Peptidyltransferase inhibitor | 0.254 0.048 DBMET00285 | DBMET00285 | |
| 0.172 | 0.104 | 0.172 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.155 0.137 DBMET00285 | ||
| 0.114 | 0.045 | 0.149 | Anabolic | 0.149 0.019 DBMET00285 | DBMET00285 | |
| 0.1 | 0.032 | 0.117 | Glycine receptor antagonist | 0.117 0.02 DBMET00285 | DBMET00285 | |
| 0.097 | 0.034 | 0.134 | Metalloproteinase-9 inhibitor | 0.134 0.02 DBMET00285 | DBMET00285 | |
| 0.128 | 0.067 | 0.128 | Cholinergic antagonist | |||
| 0.11 | 0.051 | 0.202 | UDP-glucose 4-epimerase inhibitor | 0.202 0.018 DBMET00285 | DBMET00285 | |
| 0.124 | 0.067 | 0.124 | Acetylcholine antagonist | |||
| 0.115 | 0.06 | 0.142 | 5 Hydroxytryptamine 3A agonist | 0.142 0.04 DBMET00285 | DBMET00285 | |
| 0.062 | 0.007 | 0.062 | Phosphodiesterase 6C inhibitor | 0.044 0.04 DBMET00285 | ||
| 0.116 | 0.065 | 0.116 | 5 Hydroxytryptamine 2B antagonist | |||
| 0.092 | 0.043 | 0.134 | Metalloproteinase-2 inhibitor | 0.134 0.024 DBMET00285 | DBMET00285 | |
| 0.076 | 0.026 | 0.106 | Androgen agonist | 0.106 0.013 DBMET00285 | DBMET00285 | |
| 0.062 | 0.013 | 0.073 | Thymidine kinase inhibitor | 0.073 0.01 DBMET00285 | DBMET00285 | |
| 0.113 | 0.064 | 0.113 | Alpha 2b adrenoreceptor antagonist | |||
| 0.212 | 0.166 | 0.229 | Ca(v)3.3 blocker | 0.229 0.135 DBMET00285 | DBMET00285 | |
| 0.11 | 0.067 | 0.11 | Cystathionine beta-synthase inhibitor | 0.099 0.077 DBMET00285 | ||
| 0.098 | 0.056 | 0.213 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.213 0.014 DBMET00285 | DBMET00285 | |
| 0.084 | 0.043 | 0.084 | Alpha 1b adrenoreceptor antagonist | |||
| 0.117 | 0.077 | 0.124 | DNA repair enzyme inhibitor | 0.124 0.064 DBMET00285 | DBMET00285 | |
| 0.048 | 0.008 | 0.048 | Phosphodiesterase 6B inhibitor | |||
| 0.056 | 0.016 | 0.098 | Guanylate cyclase stimulant | 0.098 0.006 DBMET00285 | DBMET00285 | |
| 0.101 | 0.061 | 0.146 | GABA C receptor rho-1 antagonist | 0.146 0.023 DBMET00285 | DBMET00285 | |
| 0.041 | 0.004 | 0.041 | Acid ceramidase inhibitor | 0.033 0.007 DBMET00285 | ||
| 0.095 | 0.06 | 0.095 | Alpha adrenoreceptor antagonist | |||
| 0.04 | 0.005 | 0.04 | DNA polymerase III inhibitor | 0.036 0.007 DBMET00285 | ||
| 0.095 | 0.061 | 0.095 | Prolactin inhibitor | 0.095 0.061 DBMET00285 | ||
| 0.099 | 0.067 | 0.099 | Alpha 2c adrenoreceptor antagonist | |||
| 0.073 | 0.041 | 0.104 | Matrix metalloproteinase inhibitor | 0.104 0.025 DBMET00285 | DBMET00285 | |
| 0.048 | 0.017 | 0.06 | Kainate receptor agonist | 0.06 0.007 DBMET00285 | DBMET00285 | |
| 0.044 | 0.013 | 0.044 | Purinergic P2Y2 antagonist | 0.033 0.024 DBMET00285 | ||
| 0.035 | 0.007 | 0.042 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.042 0.005 DBMET00285 | DBMET00285 | |
| 0.064 | 0.037 | 0.092 | Collagenase 3 inhibitor | 0.092 0.018 DBMET00285 | DBMET00285 | |
| 0.039 | 0.013 | 0.047 | Calcitonin gene-related peptide antagonist | 0.047 0.011 DBMET00285 | DBMET00285 | |
| 0.031 | 0.007 | 0.031 | Phosphodiesterase 6G inhibitor | |||
| 0.031 | 0.007 | 0.031 | Phosphodiesterase 6H inhibitor | |||
| 0.068 | 0.044 | 0.088 | MDM2 inhibitor | 0.088 0.013 DBMET00285 | DBMET00285 | |
| 0.229 | 0.204 | 0.229 | Analgesic | |||
| 0.037 | 0.013 | 0.07 | Uridine phosphorylase inhibitor | 0.07 0.004 DBMET00285 | DBMET00285 | |
| 0.075 | 0.051 | 0.075 | Phosphodiesterase VI inhibitor | |||
| 0.032 | 0.01 | 0.08 | Nicotinic acid receptor 2 antagonist | 0.08 0.003 DBMET00285 | DBMET00285 | |
| 0.067 | 0.048 | 0.067 | Glutamate (mGluR7) antagonist | 0.063 0.056 DBMET00285 | ||
| 0.06 | 0.041 | 0.06 | Alpha 1d adrenoreceptor antagonist | |||
| 0.061 | 0.042 | 0.061 | TRPA1 antagonist | 0.061 0.041 DBMET00285 | ||
| 0.084 | 0.065 | 0.105 | Interleukin 5 antagonist | 0.105 0.036 DBMET00285 | DBMET00285 | |
| 0.026 | 0.006 | 0.039 | Thymidine kinase (Herpes simplex virus 2) inhibitor | 0.039 0.003 DBMET00285 | DBMET00285 | |
| 0.057 | 0.038 | 0.067 | Pregnane X receptor antagonist | 0.067 0.018 DBMET00285 | DBMET00285 | |
| 0.145 | 0.126 | 0.145 | MAP kinase kinase 2 inhibitor | |||
| 0.06 | 0.042 | 0.06 | Phosphodiesterase 1B inhibitor | 0.056 0.047 DBMET00285 | ||
| 0.027 | 0.01 | 0.027 | Phosphodiesterase 6A inhibitor | |||
| 0.03 | 0.012 | 0.041 | Thymidine phosphorylase inhibitor | 0.041 0.006 DBMET00285 | DBMET00285 | |
| 0.025 | 0.009 | 0.062 | Guanylate cyclase 1 stimulant | 0.062 0.004 DBMET00285 | DBMET00285 | |
| 0.052 | 0.037 | 0.065 | Matrix metalloproteinase 1 inhibitor | 0.065 0.029 DBMET00285 | DBMET00285 | |
| 0.083 | 0.069 | 0.083 | Bromodomain-containing protein 2 inhibitor | 0.08 0.078 DBMET00285 | ||
| 0.099 | 0.085 | 0.122 | Adenylate cyclase inhibitor | 0.122 0.065 DBMET00285 | DBMET00285 | |
| 0.062 | 0.049 | 0.062 | 5 Hydroxytryptamine 1B antagonist | |||
| 0.016 | 0.005 | 0.016 | DNA polymerase III polC-type inhibitor | 0.016 0.005 DBMET00285 | ||
| 0.1 | 0.089 | 0.133 | Photosensitizer | 0.133 0.043 DBMET00285 | DBMET00285 | |
| 0.122 | 0.112 | 0.122 | Sigma receptor agonist | |||
| 0.055 | 0.046 | 0.117 | Biliverdin reductase inhibitor | 0.117 0.014 DBMET00285 | DBMET00285 | |
| 0.018 | 0.01 | 0.018 | Calcitonin gene-related peptide 1 receptor antagonist | 0.016 0.014 DBMET00285 | ||
| 0.035 | 0.027 | 0.077 | Nicotinic acid receptor agonist | 0.077 0.007 DBMET00285 | DBMET00285 | |
| 0.095 | 0.087 | 0.152 | GABA C receptor antagonist | 0.152 0.029 DBMET00285 | DBMET00285 | |
| 0.062 | 0.054 | 0.062 | Phosphodiesterase 4B inhibitor | |||
| 0.059 | 0.052 | 0.066 | Phosphodiesterase 1C inhibitor | 0.066 0.035 DBMET00285 | DBMET00285 | |
| 0.051 | 0.044 | 0.076 | Matrix metalloproteinase (membrane-type) inhibitor | 0.076 0.021 DBMET00285 | DBMET00285 | |
| 0.056 | 0.051 | 0.1 | NMDA 2C receptor antagonist | 0.1 0.015 DBMET00285 | DBMET00285 | |
| 0.115 | 0.11 | 0.125 | Sphingosine 1-phosphate receptor 2 antagonist | 0.125 0.086 DBMET00285 | DBMET00285 | |
| 0.188 | 0.183 | 0.188 | Thioredoxin glutathione reductase inhibitor | |||
| 0.02 | 0.016 | 0.02 | Geranylgeranyltransferase I inhibitor | |||
| 0.044 | 0.042 | 0.044 | Adenosine A2b receptor antagonist | |||
| 0.05 | 0.048 | 0.05 | 5 Hydroxytryptamine 3 antagonist | |||
| 0.042 | 0.04 | 0.052 | Parathyroid hormone antagonist | 0.052 0.018 DBMET00285 | DBMET00285 | |
| 0.076 | 0.075 | 0.076 | Antiadrenergic | |||
| 0.099 | 0.1 | 0.1 | Interleukin 8 antagonist | 0.1 0.097 DBMET00285 | DBMET00285 | |
| 0.077 | 0.078 | 0.084 | Estrogen-related receptor beta agonist | 0.084 0.056 DBMET00285 | DBMET00285 | |
| 0.006 | 0.008 | 0.018 | DNA topoisomerase III inhibitor | 0.018 0.002 DBMET00285 | DBMET00285 | |
| 0.065 | 0.067 | 0.08 | Glycine receptor agonist | 0.08 0.038 DBMET00285 | DBMET00285 | |
| 0.032 | 0.038 | 0.04 | Tryptophan 5 hydroxylase inhibitor | 0.04 0.016 DBMET00285 | DBMET00285 | |
| 0.104 | 0.114 | 0.163 | Protein kinase stimulant | 0.163 0.06 DBMET00285 | DBMET00285 | |
| 0.033 | 0.043 | 0.039 | Nicotinic acid receptor 1 agonist | 0.039 0.03 DBMET00285 | DBMET00285 | |
| 0.127 | 0.139 | 0.136 | Ca2+-transporting ATPase inhibitor | 0.136 0.091 DBMET00285 | DBMET00285 | |
| 0.027 | 0.042 | 0.06 | Nicotinic acid receptor 2 agonist | 0.06 0.011 DBMET00285 | DBMET00285 | |
| 0.049 | 0.066 | 0.089 | Neutrophil collagenase inhibitor | 0.089 0.027 DBMET00285 | DBMET00285 | |
| 0.073 | 0.091 | 0.113 | NADH dehydrogenase inhibitor | 0.113 0.033 DBMET00285 | DBMET00285 | |
| 0.045 | 0.065 | 0.088 | Dihydroorotate oxidase inhibitor | 0.088 0.008 DBMET00285 | DBMET00285 | |
| 0.043 | 0.064 | 0.074 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.074 0.023 DBMET00285 | DBMET00285 | |
| 0.011 | 0.034 | 0.022 | Thyroid hormone alpha agonist | 0.022 0.005 DBMET00285 | DBMET00285 | |
| 0.119 | 0.143 | 0.16 | Angiogenesis stimulant | 0.16 0.116 DBMET00285 | DBMET00285 | |
| 0.058 | 0.083 | 0.091 | Phospholipase D inhibitor | 0.091 0.021 DBMET00285 | DBMET00285 | |
| 0.047 | 0.073 | 0.061 | Acetylcholine M5 receptor agonist | 0.061 0.054 DBMET00285 | DBMET00285 | |
| 0.028 | 0.055 | 0.038 | Membrane dipeptidase inhibitor | 0.038 0.029 DBMET00285 | DBMET00285 | |
| 0.039 | 0.066 | 0.086 | Argininosuccinate synthase inhibitor | 0.086 0.023 DBMET00285 | DBMET00285 | |
| 0.017 | 0.046 | 0.023 | Lysophosphatidic acid receptor 1 agonist | 0.023 0.022 DBMET00285 | DBMET00285 | |
| 0.088 | 0.121 | 0.175 | Alpha-N-acetylglucosaminidase inhibitor | 0.175 0.043 DBMET00285 | DBMET00285 | |
| 0.048 | 0.082 | 0.06 | Corticotropin releasing factor 2 receptor antagonist | 0.06 0.047 DBMET00285 | DBMET00285 | |
| 0.017 | 0.051 | 0.024 | Glutamate (mGluR1) agonist | 0.024 0.018 DBMET00285 | DBMET00285 | |
| 0.015 | 0.05 | 0.036 | Glucocorticoid antagonist | 0.036 0.02 DBMET00285 | DBMET00285 | |
| 0.025 | 0.061 | 0.035 | Protein kinase (CK2) beta inhibitor | 0.035 0.019 DBMET00285 | DBMET00285 | |
| 0.035 | 0.07 | 0.073 | Aldosterone antagonist | 0.073 0.013 DBMET00285 | DBMET00285 | |
| 0.049 | 0.085 | 0.059 | Ryanodine receptor antagonist | 0.059 0.041 DBMET00285 | DBMET00285 | |
| 0.032 | 0.071 | 0.055 | Mineralocorticoid receptor antagonist | 0.055 0.024 DBMET00285 | DBMET00285 | |
| 0.032 | 0.071 | 0.053 | Adenylate cyclase 1 inhibitor | 0.053 0.024 DBMET00285 | DBMET00285 | |
| 0.111 | 0.153 | 0.133 | Sphingosine 1-phosphate receptor 5 antagonist | 0.133 0.094 DBMET00285 | DBMET00285 | |
| 0.013 | 0.056 | 0.03 | Prostaglandin EP3 antagonist | 0.03 0.021 DBMET00285 | DBMET00285 | |
| 0.074 | 0.123 | 0.097 | DNA polymerase I inhibitor | 0.097 0.09 DBMET00285 | DBMET00285 | |
| 0.017 | 0.066 | 0.034 | Fumarate hydratase inhibitor | 0.034 0.024 DBMET00285 | DBMET00285 | |
| 0.024 | 0.074 | 0.084 | NMDA 2A receptor antagonist | 0.084 0.018 DBMET00285 | DBMET00285 | |
| 0.085 | 0.138 | 0.125 | Lipid peroxidase inhibitor | 0.125 0.088 DBMET00285 | DBMET00285 | |
| 0.026 | 0.081 | 0.039 | Potassium channel Kv1.1 blocker | 0.039 0.025 DBMET00285 | DBMET00285 | |
| 0.152 | 0.208 | 0.183 | 5 Hydroxytryptamine 3E antagonist | 0.183 0.098 DBMET00285 | DBMET00285 | |
| 0.052 | 0.111 | 0.085 | Androgen antagonist | 0.085 0.06 DBMET00285 | DBMET00285 | |
| 0.035 | 0.099 | 0.091 | Phosphodiesterase III inhibitor | 0.091 0.027 DBMET00285 | DBMET00285 | |
| 0.072 | 0.137 | 0.09 | Alpha 2d adrenoreceptor antagonist | 0.09 0.07 DBMET00285 | DBMET00285 | |
| 0.064 | 0.13 | 0.14 | GABA C receptor agonist | 0.14 0.038 DBMET00285 | DBMET00285 | |
| 0.074 | 0.142 | 0.107 | Adenylate kinase inhibitor | 0.107 0.057 DBMET00285 | DBMET00285 | |
| 0.154 | 0.223 | 0.223 | Transcription factor NF kappa B inhibitor | 0.223 0.148 DBMET00285 | DBMET00285 | |
| 0.033 | 0.106 | 0.075 | Phosphofructokinase-1 inhibitor | 0.075 0.044 DBMET00285 | DBMET00285 | |
| 0.027 | 0.101 | 0.047 | Acyl-CoA dehydrogenase inhibitor | 0.047 0.046 DBMET00285 | DBMET00285 | |
| 0.031 | 0.107 | 0.059 | Carbamoyl phosphate synthetase inhibitor | 0.059 0.043 DBMET00285 | DBMET00285 | |
| 0.12 | 0.197 | 0.164 | Neurotensin receptor agonist | 0.164 0.072 DBMET00285 | DBMET00285 | |
| 0.056 | 0.136 | 0.127 | HIV-1 integrase (Overall Integration) inhibitor | 0.127 0.035 DBMET00285 | DBMET00285 | |
| 0.095 | 0.179 | 0.247 | Growth hormone agonist | 0.247 0.044 DBMET00285 | DBMET00285 | |
| 0.021 | 0.107 | 0.047 | Thymidylate synthase inhibitor | 0.047 0.032 DBMET00285 | DBMET00285 | |
| 0.018 | 0.107 | 0.037 | Dopamine D5 agonist | 0.037 0.033 DBMET00285 | DBMET00285 | |
| 0.049 | 0.142 | 0.1 | Keratolytic | 0.1 0.03 DBMET00285 | DBMET00285 | |
| 0.026 | 0.12 | 0.059 | NMDA receptor glycine site agonist | 0.059 0.047 DBMET00285 | DBMET00285 | |
| 0.013 | 0.11 | 0.026 | Thyroid hormone agonist | 0.026 0.018 DBMET00285 | DBMET00285 | |
| 0.142 | 0.241 | 0.211 | Nitric-oxide synthase stimulant | 0.211 0.071 DBMET00285 | DBMET00285 | |
| 0.063 | 0.165 | 0.109 | AMP-activated protein kinase stimulant | 0.109 0.06 DBMET00285 | DBMET00285 | |
| 0.024 | 0.127 | 0.059 | Alcohol oxidase inhibitor | 0.059 0.036 DBMET00285 | DBMET00285 | |
| 0.094 | 0.2 | 0.142 | Adenylate cyclase stimulant | 0.142 0.077 DBMET00285 | DBMET00285 | |
| 0.062 | 0.184 | 0.097 | Microtubule formation inhibitor | 0.097 0.096 DBMET00285 | DBMET00285 | |
| 0.03 | 0.158 | 0.072 | Porphobilinogen synthase inhibitor | 0.072 0.054 DBMET00285 | DBMET00285 | |
| 0.101 | 0.235 | 0.163 | Succinate dehydrogenase inhibitor | 0.163 0.091 DBMET00285 | DBMET00285 | |
| 0.05 | 0.187 | 0.085 | Triose-phosphate isomerase inhibitor | 0.085 0.068 DBMET00285 | DBMET00285 | |
| 0.042 | 0.181 | 0.064 | Glutamate (mGluR6) antagonist | 0.064 0.055 DBMET00285 | DBMET00285 | |
| 0.1 | 0.24 | 0.164 | Neurotrophic factor enhancer | 0.164 0.118 DBMET00285 | DBMET00285 | |
| 0.076 | 0.221 | 0.143 | Arachidonic acid antagonist | 0.143 0.097 DBMET00285 | DBMET00285 | |
| 0.176 | 0.321 | 0.279 | Calcium channel L-type activator | 0.279 0.175 DBMET00285 | DBMET00285 | |
| 0.099 | 0.248 | 0.135 | ATPase inhibitor | 0.135 0.129 DBMET00285 | DBMET00285 | |
| 0.052 | 0.213 | 0.081 | Granulocyte macrophage colony stimulating factor agonist | 0.081 0.072 DBMET00285 | DBMET00285 | |
| 0.065 | 0.227 | 0.145 | Peroxidase inhibitor | 0.145 0.08 DBMET00285 | DBMET00285 | |
| 0.181 | 0.343 | 0.333 | 5 Hydroxytryptamine release inhibitor | 0.333 0.131 DBMET00285 | DBMET00285 | |
| 0.078 | 0.252 | 0.165 | Interleukin agonist | 0.165 0.153 DBMET00285 | DBMET00285 | |
| 0.071 | 0.25 | 0.115 | Mannose-6-phosphate isomerase inhibitor | 0.115 0.11 DBMET00285 | DBMET00285 | |
| 0.056 | 0.243 | 0.095 | DOPA decarboxylase inhibitor | 0.095 0.086 DBMET00285 | DBMET00285 | |
| 0.027 | 0.222 | 0.075 | NMDA receptor antagonist | 0.075 0.072 DBMET00285 | DBMET00285 | |
| 0.117 | 0.338 | 0.202 | Insulysin inhibitor | 0.202 0.154 DBMET00285 | DBMET00285 | |
| 0.029 | 0.254 | 0.091 | Alcohol dehydrogenase inhibitor | 0.091 0.063 DBMET00285 | DBMET00285 | |
| 0.075 | 0.307 | 0.14 | 3C-like protease (Human coronavirus) inhibitor | 0.14 0.12 DBMET00285 | DBMET00285 | |
| 0.075 | 0.313 | 0.133 | CF transmembrane conductance regulator agonist | 0.133 0.112 DBMET00285 | DBMET00285 | |
| 0.115 | 0.387 | 0.219 | Calcium channel activator | 0.219 0.186 DBMET00285 | DBMET00285 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |